Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| iBio, Inc.IBIO · Entity 6906 | Director | June 12, 2020 | October 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
iBio, Inc.
Report date June 12, 2020 · Filed October 28, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2030-06-12 | Direct | 400,000 |
Reported balance
After 2020-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-06-12 · Grant · Acquired 400,000 · Balance 400,000 F1: This amendment on Form 4/A is being filed to amend the original Form 4 filed by the reporting person on June 16, 2020 (the "Original Form 4") solely to amend the exercise price in Column 2 of Table II which was incorrectly reported in the Original Form 4. All other information in the Original Form 4 remains unchanged. F2: Immediate vesting as to 50,000 shares of Common Stock underlying the option and the remaining shares vest pro rata on a monthly basis over the next 21 months. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment on Form 4/A is being filed to amend the original Form 4 filed by the reporting person on June 16, 2020 (the "Original Form 4") solely to amend the exercise price in Column 2 of Table II which was incorrectly reported in the Original Form 4. All other information in the Original Form 4 remains unchanged.
F2: Immediate vesting as to 50,000 shares of Common Stock underlying the option and the remaining shares vest pro rata on a monthly basis over the next 21 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2020 Filed Jun 16, 2020 21:16 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option · Derivative | 400,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001104659-20-073831 · tm2022528d1_4.xml · derivative · entry 1 Kay Robert · CIK 0001285612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-06-12 F1 · shares: Immediate vesting as to 50,000 shares of Common Stock underlying the option and the remaining shares vest pro rata on a monthly basis over the next 21 months. Read SEC document |
| June 12, 2020 Filed Oct 28, 2020 18:40 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option · Derivative | 400,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001104659-20-118870 · tm2034091d1_4.xml · derivative · entry 1 Kay Robert · CIK 0001285612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2030-06-12 F1 · derivative.exercise_price: This amendment on Form 4/A is being filed to amend the original Form 4 filed by the reporting person on June 16, 2020 (the "Original Form 4") solely to amend the exercise price in Column 2 of Table II which was incorrectly reported in the Original Form 4. All other information in the Original Form 4 remains unchanged. F2 · shares: Immediate vesting as to 50,000 shares of Common Stock underlying the option and the remaining shares vest pro rata on a monthly basis over the next 21 months. Read SEC document |
| April 01, 2019 Filed May 31, 2019 20:19 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.90 Strike: $0.90 | $45,000.00 |
DisclosureSEC source: 0001638599-19-000583 · doc4_6097.xml · derivative · entry 1 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,500 Underlying: Common Stock · 50,000 shares Expires 2029-04-01 Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 20 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 19 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-01 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 56,250 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 18 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 56,250 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $17.20 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 17 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 75,000 shares Expires 2025-09-04 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 16 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 45,000 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 15 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 60,000 shares Expires 2024-09-05 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 14 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 13 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 30,000 shares Expires 2023-07-16 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 12 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 11 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 30,000 shares Expires 2022-07-24 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 10 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $19.60 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 9 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 30,000 shares Expires 2021-10-21 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 37,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 8 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 37,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $30.70 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 7 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 50,000 shares Expires 2020-12-30 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 37,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 6 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 37,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $30.70 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 5 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 50,000 shares Expires 2020-12-30 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 4 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $17.30 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 3 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 30,000 shares Expires 2020-08-16 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F6 · derivative.exercise_date: Vested 20% on 7/1/2010 and then in 20% instalments on each anniversary thereof. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 18,750 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 2 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 18,750 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 13, 2019 15:31 UTC | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001638599-19-000510 · doc4_6052.xml · derivative · entry 1 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,000 Underlying: Common Stock · 25,000 shares Expires 2019-08-10 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 20 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 19 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 30,000 shares Expires 2027-05-01 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 56,250 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 18 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 56,250 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $17.20 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 17 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 75,000 shares Expires 2025-09-04 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 16 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 45,000 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 15 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 60,000 shares Expires 2024-09-05 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 14 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 13 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 30,000 shares Expires 2023-07-16 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 12 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 11 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 30,000 shares Expires 2022-07-24 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 10 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $19.60 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 9 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 30,000 shares Expires 2021-10-21 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 37,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 8 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 37,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $30.70 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 7 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 50,000 shares Expires 2020-12-30 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 37,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 6 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 37,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | Not disclosed Strike: $30.70 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 5 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 50,000 shares Expires 2020-12-30 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F7 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 22,500 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 4 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 22,500 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $17.30 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 3 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 30,000 shares Expires 2020-08-16 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F6 · derivative.exercise_date: Vested 20% on 7/1/2010 and then in 20% instalments on each anniversary thereof. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 18,750 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 2 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 18,750 shares Expires 2024-02-20 F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person. F4 · derivative.exercise_date: Fully vests on first anniversary of grant date. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| February 20, 2019 Filed May 31, 2019 20:16 UTC Amendment | iBio, Inc. IBIO · Entity 6906 | Disposition to issuerStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001638599-19-000574 · doc4a_6128.xml · derivative · entry 1 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,500 Underlying: Common Stock · 25,000 shares Expires 2019-08-10 F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options. F1 · derivative.exercise_date: Vested in five annual instalments on anniversaries of date of grant. F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4/A. F8 · balance_after: This report on Form 4/A corrects an error with respect to the Amount of Securities Beneficially Owned Following Reported Transaction. Read SEC document |
| May 01, 2017 Filed Jun 16, 2017 15:07 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.40 Strike: $0.40 | $120,000.00 |
DisclosureSEC source: 0001638599-17-000609 · doc4_4800.xml · derivative · entry 1 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,350,000 Underlying: Common Stock · 300,000 shares Expires 2027-05-01 F1 · derivative.exercise_date: Vests in equal annual installments over three years beginning 12/1/16. Read SEC document |
| September 04, 2015 Filed Apr 5, 2017 21:16 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 750,000 | $1.72 Strike: $1.72 | $1,290,000.00 |
DisclosureSEC source: 0001638599-17-000357 · doc4_4657.xml · derivative · entry 2 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,050,000 Underlying: Common Stock · 750,000 shares Expires 2025-09-04 F2 · derivative.exercise_date: (2) Vesting starts 7/1/2015, in equal annual installments over three years. Read SEC document |
| September 05, 2014 Filed Apr 5, 2017 21:16 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 600,000 | $1.00 Strike: $1.00 | $600,000.00 |
DisclosureSEC source: 0001638599-17-000357 · doc4_4657.xml · derivative · entry 1 Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,300,000 Underlying: Common Stock · 600,000 shares Expires 2024-09-05 F1 · derivative.exercise_date: (1) Vesting starts 7/1/2014, in equal annual installments over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.